Roman-Ulrich Müller

scientist and MD, aiming to bring novel strategies to fight kidney disease from basic research to the clinic with a focus on dietary and metabolic interventions

[Roman-Ulrich Müller @MuellerRom]

1/
🚨 Big news from our Genes&Kidney Working Group at the @ERAkidney
We just released a consensus statement in Nephrology Dialysis Transplantation aiming to bring us closer to precision medicine in CKD. 🧬🩺
🧵 THREAD 👇

[Roman-Ulrich Müller @MuellerRom]

A recent survey study performed by the @ERAkidney WG Genes&Kidney addresses this question and highlights how current recommendations are implemented in real-world care.

https://t.co/P71cFBzmzi

[Roman-Ulrich Müller @MuellerRom]

The fact that primary hyperoxaluria is the first kidney disease for which an RNA therapeutic has become available is a milestone for the field.

How does this change the treatment landscape? 🧵

[PKD International @PKD_Int]

🧵🧪 STOP-PKD study | Expanding recruitment across Europe : https://t.co/OntDB0Jp8z

The STOP-PKD study continues to expand, marking an important step forward for ADPKD research in Europe.

[Roman-Ulrich Müller @MuellerRom]

@AlanYuNeph Thank you Alan.

[Roman-Ulrich Müller @MuellerRom]

I usually think twice before posting preprints. But this time it’s different.
MEDA-PKD is the essence of our work over more than a decade — and, to me, one of the most meaningful contributions I’ve been able to make to biomedical research.
🧵

[Roman-Ulrich Müller @MuellerRom]

@NicolaMTomas Thanks Nicola

[Roman-Ulrich Müller @MuellerRom]

Huge thanks to all collaborators, clinicians, study nurses, researchers, data scientists — and especially the patients contributing to this effort.
@UKKoeln @UniCologne @CECAD_ @PKD_Int

[Roman-Ulrich Müller @MuellerRom]

More broadly, MEDA points toward:
➡️continuously learning health systems
➡️real-time translational research
➡️scalable precision medicine infrastructures

📄Preprint:
https://t.co/HBRvDzhSDD
🖥️ Live dashboard:
https://t.co/Edesmi4tLI

[Roman-Ulrich Müller @MuellerRom]

First results of the growing interaction between the Nephrology Research Units at Uniklinik Köln and Universitätsklinikum Düsseldorf.

Urine Proteomics as a Source of Biological Information and Outcome Pre... https://t.co/t8XMAajDKC

[PKD International @PKD_Int]

🧵 We are pleased to announce that the UMCG Universitair Medisch Centrum Groningen in the Netherlands is now officially accredited as a trial site for the STOP-PKD Study.

[PKD International @PKD_Int]

🧵 4/4 Help shape the future of #ADPKD research in Europe 🔬 - make your voice count!

📲 Take part now:
https://t.co/aHBWz9PgNc

🗣️ Every response strengthens the patient voice. Thank you! 💛

@FLAVIAZH
@MuellerRom
@UKKoeln

[Roman-Ulrich Müller @MuellerRom]

@ArevaloGoJairo @UKKoeln @UniCologne Essentially we do not know yet if carb restriction works. The ketogenic diet-adpkd study was promising… but we lack a large phase 3 like trial and are currently trying to obtain funding for this

[Roman-Ulrich Müller @MuellerRom]

Thanks for the support. More info at https://t.co/nQMbQ9V9P7
@UKKoeln @UniCologne

[PKD International @PKD_Int]

🧵🧪 Important recruitment update on the STOP-PKD study (1/6)
We are very pleased to share a significant update on the #STOP-PKD study, an important European research initiative for people living with #ADPKD.

[Roman-Ulrich Müller @MuellerRom]

🚀 STOP-PKD-News!

Das zweite Prüfzentrum in Mainz ist nun offiziell freigegeben. Weitere folgen (DE, NL, ES, AT).

Kann SGLT2-Inhibition das Fortschreiten von Zystennieren positiv beeinflussen?

Infos und Kontakte: https://t.co/6KKGuAQBXp

#STOPPKD #ADPKD
@PKD_Int

[Roman-Ulrich Müller @MuellerRom]

@JochenReiser Sorry about that. Will be corrected.

[Roman-Ulrich Müller @MuellerRom]

Inflammation is a driver of disease progression in ADPKD and a potential therapeutic target. In this systematic review, we summarise current knowledge on the role of immune cells.

The Role of Immune Cells as Modulators of Progression in... : Kidney360 https://t.co/xIYu5Yb2PO